Below is an outline of the companies in which BioTime has a direct or indirect ownership, their respective principal fields of business and BioTime’s percentage ownership.

Company

 

Field of Business

 

BioTime Ownership

 

OncoCyte Corporation (NYSE American: OCX)

 

Cancer diagnostics

    28%  

AgeX Therapeutics, Inc. (NYSE American: AGE)

 

PureStem® progenitor cell lines, brown adipose fat, induced tissue regeneration technology

    5%  

Cell Cure Neurosciences Ltd.

 

R&D and manufacturing of BioTime’s cell replacement platform technology

    99%  

Asterias Biotherapeutics, Inc.

 

Cell based therapeutics to treat neurological conditions

    100%  

ES Cell International Pte. Ltd

 

Research and clinical grade cell lines

    100%  

OrthoCyte Corporation

 

Research in orthopedic diseases and injuries

    99.8%